The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

The present disclosure relates to a composition comprising eleutheroside-C, pinitol and sugars optionally along with pharmaceutically acceptable excipient or a combination thereof; a process of obtaining said composition from fenugreek seeds, a method of treating neuropathic pain or managing neuropathy, and the use of the said composition in treating neuropathic pain or managing neuropathy.

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

An antimicrobial mixture comprising or consisting of: one or more compounds of the formula (I) ##STR00001## their salts or solvates, wherein R.sup.1 and R.sup.2 in each case independently of one another are chosen from the group consisting of: H, OH, F, Cl, Br and I, and wherein X in each case denotes:
(CH.sub.2).sub.m where m=1, 2 or 3 or
OCH.sub.2.sub.n where n=1, 2 or 3 or
OCH.sub.2CH(R.sup.3) where R.sup.3=CH.sub.3 or CH.sub.2OH or
(CH.sub.2O.sub.pCH.sub.2 where p=1 or 2, wherein in the compound(s) of the formula I a primary alcohol function CH.sub.2OH is optionally replaced by a radical which is chosen from the group consisting of CH.sub.2OR.sup.4, COOH and COOR.sup.4 and/or a secondary alcohol function CHOH is optionally replaced by the radical CHOR.sup.4, wherein each R.sup.4 denotes an aliphatic or aromatic radical, independently of the meaning of further radicals, and one, two or more compounds chosen from the group consisting of the tropolones of the formula (II) ##STR00002## wherein the substituents R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR.sup.10, wherein R.sup.10 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR.sup.11, wherein R.sup.11 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO.sub.2, NH.sub.2, F, Cl, Br, I.

An antimicrobial mixture comprising or consisting of: one or more compounds of the formula (I) ##STR00001## their salts or solvates, wherein R.sup.1 and R.sup.2 in each case independently of one another are chosen from the group consisting of: H, OH, F, Cl, Br and I, and wherein X in each case denotes:
(CH.sub.2).sub.m where m=1, 2 or 3 or
OCH.sub.2.sub.n where n=1, 2 or 3 or
OCH.sub.2CH(R.sup.3) where R.sup.3=CH.sub.3 or CH.sub.2OH or
(CH.sub.2O.sub.pCH.sub.2 where p=1 or 2, wherein in the compound(s) of the formula I a primary alcohol function CH.sub.2OH is optionally replaced by a radical which is chosen from the group consisting of CH.sub.2OR.sup.4, COOH and COOR.sup.4 and/or a secondary alcohol function CHOH is optionally replaced by the radical CHOR.sup.4, wherein each R.sup.4 denotes an aliphatic or aromatic radical, independently of the meaning of further radicals, and one, two or more compounds chosen from the group consisting of the tropolones of the formula (II) ##STR00002## wherein the substituents R.sup.5, R.sup.6, R.sup.7, R.sup.8, R.sup.9 independently of one another have the following meaning: H; linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; OH; OR.sup.10, wherein R.sup.10 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; COOH; COOR.sup.11, wherein R.sup.11 is a linear or branched, saturated or unsaturated, aliphatic hydrocarbon radical having up to 30 C atoms; NO.sub.2, NH.sub.2, F, Cl, Br, I.

This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa destructor resistance, compared to an acaricide. The compounds can work in conjunction with other mite control approaches, such as a bottom board excluder and sticky board control devices, and can enhance the performance of other forms of mite control while decreasing disadvantages associated therewith.

This disclosure describes compounds that affect the olfactory responses of the honey bee mite (Varroa destructor) and methods of use thereof. The compounds do not kill Varroa destructor, and are therefore unlikely to generate Varroa destructor resistance, compared to an acaricide. The compounds can work in conjunction with other mite control approaches, such as a bottom board excluder and sticky board control devices, and can enhance the performance of other forms of mite control while decreasing disadvantages associated therewith.

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.